Trial Profile

Phase 2 study of APL-1202 for the treatment of Free-living Amoebae Infections infections

Status: Not stated

Phase of Trial: Phase II

Latest Information Update: 28 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nitroxoline (Primary)
Indications Amoebiasis
Focus Therapeutic Use

Most Recent Events

28 Apr 2025 New trial record
24 Jun 2024 According to Asieris Pharmaceuticals media release, company announced that its Investigational New Drug (IND) for investigational drug APL-1202 (nitroxoline) has been approved for the treatment of Free-living Amoebae (FLA) infections by Center for Drug Evaluation (CDE), part of the National Medical Products Administration (NMPA).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com